Skip to content
value.today

Carmell Therapeutics Corp

Total raised
$13 M
5 rounds on record
Latest round
$2 M
Sep 2019
First round on record
Apr 2011
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Carmell Therapeutics Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2019$2 MNo. 5$2 to $10 million

Carmell Therapeutics Corp: Raise no. 5, Sep 2019

Investors in this round

37 investors had bought by the notice of Sep 25, 2020: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$37,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donna Godward · Executive Officer
  • James Hart · Executive Officer
  • Randolph Hubbell · Executive Officer, Director
  • Stephanie W. Kladakis · Executive Officer
  • David W. Anderson · Director
  • Richard Upton · Director
  • Wendy W. DiCicco · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Alere Financial Partners (CRD 109761) · Syosset, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “Offering consists of $3,200,000 of Convertible Notes and $300,000 of Warrants”

Signed by Randolph W. Hubbell, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Sep 25, 2020. Read the notice at the SEC.

debt, optionsSEC
Jul 2018$5 MNo. 4$2 to $10 million

Carmell Therapeutics Corp: Raise no. 4, Jul 2018

Investors in this round

44 investors had bought by the notice of Mar 14, 2019: 44 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $8 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$855,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donna Godward · Executive Officer
  • James Hart · Executive Officer
  • Randolph Hubbell · Executive Officer, Director
  • Stephanie W. Kladakis · Executive Officer
  • David W. Anderson · Director
  • James F. Jordan · Director
  • Richard Upton · Director
  • Wendy W. DiCicco · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Dalmore Group, LLC (CRD 136352) · Woodmere, New YorkSold in AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, VT, WA, WI, WV, WY

Remarks in the notice

  • On fees: “Represents up to 9% placement agent fee.”

Signed by Randolph W. Hubbell, Chief Executive Officer and President. Source: SEC Form D and 1 amendment, newest notice filed Mar 14, 2019. Read the notice at the SEC.

debt, optionsSEC
Sep 2017$2 MNo. 3Under $2 million

Carmell Therapeutics Corp: Raise no. 3, Sep 2017

Investors in this round

25 investors had bought by the notice of Dec 6, 2017: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
$3,741
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donna Godward · Executive Officer
  • James Hart · Executive Officer
  • Randolph Hubbell · Executive Officer, Director
  • Stephanie W. Kladakis · Executive Officer
  • David W. Anderson · Director
  • James F. Jordan · Director
  • Richard Upton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Randolph W. Hubbell, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Dec 6, 2017. Read the notice at the SEC.

equitySEC
Dec 2016$1 MNo. 2Under $2 million

Carmell Therapeutics Corp: Raise no. 2, Dec 2016

Investors in this round

25 investors had bought by the notice of Apr 14, 2017: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Donna Godward · Executive Officer
  • James Hart · Executive Officer
  • Randolph Hubbell · Executive Officer, Director
  • Stephanie W. Kladakis · Executive Officer
  • David W. Anderson · Director
  • James F. Jordan · Director
  • Richard Upton · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Randolph Hubbell, Chief Executive Officer and President. Source: SEC Form D, newest notice filed Apr 14, 2017. Read the notice at the SEC.

equity, optionsSEC
Apr 2011$2 MNo. 1$2 to $10 million

Carmell Therapeutics Corp: Raise no. 1, Apr 2011

Investors in this round

9 investors had bought by the notice of Apr 13, 2011: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan I. West · Executive Officer, Director
  • J. Michael Egan · Director
  • James Michael Jordan · Director
  • Paul Michael Kornblith · Director
  • Richard Michael Upton · Director
  • William Michael Newlin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alan I. West, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 13, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Carmell Therapeutics Corp chose not to state its revenue in its newest notice of a funding round (Sep 2020).

    SEC Form D · Sep 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2020

That is all the official record says: Carmell Therapeutics Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Carmell Therapeutics Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 44 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Carmell Therapeutics Corp
NameRoleNamed in
Donna GodwardExecutive officerSep 2020
James HartExecutive officerSep 2020
Randolph HubbellExecutive officerSep 2020
Stephanie W. KladakisExecutive officerSep 2020
Alan I. WestExecutive officerApr 2011
David W. AndersonDirectorSep 2020
Randolph HubbellDirectorSep 2020
Richard UptonDirectorSep 2020
Wendy W. DiCiccoDirectorSep 2020
James F. JordanDirectorMar 2019
Alan I. WestDirectorApr 2011
J. Michael EganDirectorApr 2011
James Michael JordanDirectorApr 2011
Paul Michael KornblithDirectorApr 2011
Richard Michael UptonDirectorApr 2011
William Michael NewlinDirectorApr 2011